Ptc Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
PTC Therapeutics achieved significant regulatory approvals for Sephience and Kebilidi in 2025, driving substantial revenue growth despite challenges with Translarna's EU marketing authorization.
NASDAQ
10-K: PTC Therapeutics Reports Promising Pipeline Progress in 2024, Faces Translarna Uncertainty in Europe
PTC Therapeutics highlights pipeline advancements, including regulatory submissions for sepiapterin and vatiquinone, while navigating potential challenges to Translarna's marketing authorization in Europe.
NASDAQ
PTC Therapeutics has amended its royalty purchase agreement with Royalty Pharma, securing $1 billion upfront for a portion of its Evrysdi royalties and retaining options for further sales.